inhaled insulin

Will Insulin Pricing Be MannKind Corporation's Downfall?
Will Insulin Pricing Be MannKind Corporation's Downfall?
Motley Fool
MannKind
diabetes
insulin
inhaled insulin
Afrezza
drug pricing
Flag link:
MannKind’s Afrezza Remains in Sanofi’s Plans, RBC Says
MannKind’s Afrezza Remains in Sanofi’s Plans, RBC Says
Barron's
MannKind
inhaled insulin
Afrezza
diabetes
Sanofi
Flag link:
What the Market is Telling MannKind
What the Market is Telling MannKind
24/7 Wall St
MannKind
Afrezza
insulin
inhaled insulin
Sanofi
Flag link:
Did MannKind Find Right Afrezza Partner in Sanofi?
Did MannKind Find Right Afrezza Partner in Sanofi?
Barron's
MannKind
Afrezza
Sanofi
diabetes
inhaled insulin
insulin
Flag link:
Sanofi fills some big shoes in $925M Afrezza pact with MannKind
Sanofi fills some big shoes in $925M Afrezza pact with MannKind
Fierce Biotech
Sanofi
MannKind
insulin
Afrezza
inhaled insulin
diabetes
Flag link:
Sanofi bets on inhaled insulin with up to $925 mln MannKind deal
Sanofi bets on inhaled insulin with up to $925 mln MannKind deal
Yahoo/Reuters
MannKind
Sanofi
diabetes
inhaled insulin
Afrezza
insulin
Flag link:
MannKind Afrezza Partnership News Coming Within Weeks
MannKind Afrezza Partnership News Coming Within Weeks
The Street
Afrezza
MannKind
diabetes
inhaled insulin
Flag link:
Afrezza Is A Brilliant Technology Without A Compelling Marketing Story
Afrezza Is A Brilliant Technology Without A Compelling Marketing Story
Seeking Alpha
Afrezza
diabetes
MannKind
inhaled insulin
Flag link:
MannKind's Afrezza Approved but Will Doctors Prescribe It?
MannKind's Afrezza Approved but Will Doctors Prescribe It?
Motley Fool
MannKind
Afrezza
insulin
diabetes
inhaled insulin
Flag link:
MannKind’s Afrezza: Too Niche?
MannKind’s Afrezza: Too Niche?
Barron's
MannKind
Afrezza
diabetes
insulin
inhaled insulin
Flag link:
Afrezza Approval Opens The Door To Multi-Billion Dollar Markets For MannKind
Afrezza Approval Opens The Door To Multi-Billion Dollar Markets For MannKind
Seeking Alpha
FDA
inhaled insulin
insulin
Afrezza
MannKind
diabetes
Flag link:
MannKind: No Surprises, Big Hit
MannKind: No Surprises, Big Hit
Barron's
MannKind
inhaled insulin
Afrezza
diabetes
Flag link:
MannKind Wins U.S. FDA Approval for Inhaled Insulin
MannKind Wins U.S. FDA Approval for Inhaled Insulin
Bloomberg
MannKind
FDA
inhaled insulin
Afrezza
diabetes
insulin
Flag link:
As Predicted, MannKind Starting Emotionally Fueled Run To FDA Approval, When It May Be Best To Go Short
As Predicted, MannKind Starting Emotionally Fueled Run To FDA Approval, When It May Be Best To Go Short
Seeking Alpha
FDA
diabetes
inhaled insulin
MannKind
Afrezza
Flag link:
MannKind: Approval For Afrezza Looking More And More Positive As Investors Await FDA Decision
MannKind: Approval For Afrezza Looking More And More Positive As Investors Await FDA Decision
Seeking Alpha
MannKind
diabetes
inhaled insulin
Afrezza
Flag link:
FDA Keeps Driving Up Future Cost of Inhalable Insulin
FDA Keeps Driving Up Future Cost of Inhalable Insulin
Yahoo/247WallStreet
FDA
inhaled insulin
diabetes
Afrezza
MannKind
Flag link:
Will The Third Time Be A Charm For MannKind? Leading Fund Managers Definitely Think So
Will The Third Time Be A Charm For MannKind? Leading Fund Managers Definitely Think So
Seeking Alpha
MannKind
Afrezza
inhaled insulin
diabetes
Flag link:
MannKind Wins U.S. Panel Backing for Its Inhaled Insulin
MannKind Wins U.S. Panel Backing for Its Inhaled Insulin
Bloomberg
MannKind
inhaled insulin
Afrezza
FDA
diabetes
advisory panels
Flag link:
Biotech Stock Mailbag Extra: MannKind's Afrezza Panel Setup
Biotech Stock Mailbag Extra: MannKind's Afrezza Panel Setup
TheStreet.com
advisory panels
FDA
Afrezza
diabetes
MannKind
inhaled insulin
Flag link:
MannKind announces FDA acknowledgement of NDA resubmission for Afrezza
MannKind announces FDA acknowledgement of NDA resubmission for Afrezza
Yahoo/Fly on the Wall
diabetes
inhaled insulin
MannKind
FDA
Afrezza
Flag link:

Pages